An Underrecognized Risk
Lipoprotein(a), or Lp(a), is a cholesterol-carrying particle whose blood level is determined almost entirely by genetics and remains largely stable throughout life. Elevated Lp(a) is an independent risk factor for heart attack, stroke, and aortic valve disease, and it affects roughly one in five people — yet it is rarely measured in routine care, leaving many people unaware of a significant inherited cardiovascular risk.
Why It Deserves Attention
Because Lp(a) is genetic, standard lifestyle measures and typical cholesterol treatments do little to lower it, which historically made testing feel futile. But knowing one Lp(a) level is valuable regardless: it identifies people who need more aggressive management of all their other, modifiable risk factors, and it flags families who should be screened. A single test can reveal a lifelong risk that would otherwise remain hidden behind normal-looking standard cholesterol panels.
The Changing Landscape
The importance of Lp(a) is growing because targeted therapies to lower it are in advanced clinical trials, potentially offering the first specific treatment for this risk factor. In the meantime, people with elevated Lp(a) benefit from intensive control of blood pressure, LDL cholesterol, and other risks. Experts increasingly recommend testing Lp(a) at least once in adulthood. Facilities can source diagnostic equipment and lab supplies from our catalog.
